XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.3
STOCKHOLDERS' EQUITY (Tables)
9 Months Ended
Sep. 30, 2025
STOCKHOLDERS' EQUITY [Abstract]  
Schedule Common stock repurchase
A summary of common stock repurchase activity under the Repurchase Program is as follows:
  
                          
  Three Months Ended September 30,    Nine Months Ended September 30,
  2025    2024    2025   2024
(In thousands)
             
Shares repurchased
   512     n/a       1,329         n/a  
Total cost of shares repurchased
 $ 8,040     n/a     $ 23,188         n/a  
Schedule of Assumptions The following assumptions were used to determine the fair value of options granted during the nine months ended September 30, 2025 and 2024:
               
    Nine Months ended September 30,  
      2025       2024  
Expected term
    5.5 - 6.3 years       5.5 - 6.3 years  
Volatility
   66 %    66 %
Dividend yield
   0.0      0.0  
Risk-free interest rate
   4.40 %     4.16-4.34
%
Schedule of Option Activity
A summary of the Company’s option activity under the Company’s equity incentive plans and related information is as follows:
  
                 
    Shares     Weighted-
Average
Exercise Price
 
Options outstanding, vested and expected to vest at December 31, 2024
    5,141,516     $ 3.90  
Forfeited
    (205,024   $ 2.78  
Expired
    (1,125   $ 2.21  
Granted
    683,720     $ 16.10  
Exercised
    (920,007   $ 3.38  
Options outstanding, vested and expected to vest at September 30, 2025
    4,699,080     $ 5.83  
                 
Options exercisable
    2,758,497     $ 3.78  
Schedule of Unvested RSU Activity
The Company’s RSUs generally vest annually over a period of four years for employees and semi-annually over a period of one year for directors. A summary of the Company’s unvested RSU activity and related information is as follows:
  
              
     Shares  
 Weighted-
Average Grant
Date Fair Value
 
Balance at December 31, 2024
  5,745,990    $ 5.50  
Granted
  1,874,865    $ 16.35  
Vested
  (1,839,902  $ 5.19  
Forfeited
  (552,689  $ 8.71  
Balance at September 30, 2025
  5,228,264    $ 9.16  
Schedule of Stock-Based Compensation Expense
Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for the three and nine months ended September 30, 2025 and 2024 was as follows:
  
                             
    Three Months ended September 30,   Nine Months ended September 30,
(in thousands)   2025   2024   2025   2024
Research and development
  $ 54    $ 24    $ 145    $ 65 
Plasma center operating expenses
    132      44      310      131 
Selling, general and administrative
    3,935      2,714      11,762      6,960 
Cost of product revenue
    926      397      2,417      1,027 
Total stock-based compensation expense
  $ 5,047    $ 3,179    $ 14,634    $ 8,183